Reaction profile

The FDA adverse-event record for pyoderma

1,368 FDA reports name pyoderma, a high-volume reaction in the CVM extract (VeDDRA 961). Plate stamps and neighbourhood peers follow.

#307 of 2,481
by report volume (all reactions)
1,368
reports citing this reaction
6.3%
death-coded share
Dog
most-affected species

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Pyoderma has 1,368 reports now versus 1,357 in that prior snapshot: 11 more (0.8%).

Report change
+11
Death-coded reports
+0
Death-coded share
−0.1 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Pyoderma changes

FDA AER · VeDDRA plate

Code 961 VOL-MID

VOL-MID · DEATH-PAR · UPPER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

  • VOL-MID 1,368 reports
  • DEATH-PAR 6.3%
  • UPPER-Q #307/2481
  • PHOTO-FINISH Alopecia local
  • SPECIES-DOG Dog · 1,270
  • DRUG-LEAD Oclacitinib Malea… · 211
  • DESK-WIDE 20 breeds
  • BOOK-FULL 8/8 fields

Nearest volume peer: Alopecia local (±3 reports)

Upper-third report volume drives the scale stamps on this plate; death-coded share and co-report peers follow. Not a clinical diagnosis.

High-volume neighbourhood around Pyoderma

Upper-third volume poles plus nearest peers, not a full reaction corpus board reprint.

Vomiting · highest174348Decreased red blood c… · near1394Glucosuria · near1391Incorrect dose admini… · near1382Pyoderma · this reaction1368Alopecia local · near1365Urinary tract neoplas… · low…10
FDA AER report volume · neighbourhood around Pyoderma

Pyoderma: low death-coded share in the FDA AER plate

Signature read: 1,368 reports place Pyoderma in the upper third of FDA AER volume (#307 of 2,481). Report volume is upper-third scale: 1,368 named reports in the openFDA extract. Death-coded share is lower-third: 86 of 1,368 reports (6.3% of named reports). Nearest volume peer: Alopecia local (±3 reports). Lead species Dog (1,270). Lead co-reported drug Oclacitinib Maleate (211).

Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Oclacitinib Maleate appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 1,270
Cat 96
Horse 1
Human 1

Breeds Most Affected

Retriever - Labrador 143
Crossbred Canine/dog 93
Shepherd Dog - German 78
Retriever - Golden 70
Pit Bull 48
Domestic Shorthair 47
Shih Tzu 42
Bulldog 32
Terrier - Yorkshire 31
Boxer (German Boxer) 30

Associated Drugs

Oclacitinib Maleate 211
Milbemycin Oxime + Spinosad 204
Spinosad 95
Trilostane 95
Fluralaner Chew Tablets 84
Afoxolaner 81
Carprofen 72
Cyclosporine 66
Prednisone 64
Bedinvetmab 59
Anti-Il31 Mab Mcs Lot #1283563 56
Selamectin 49
Milbemycin Oxime + Praziquantel 42
Cephalexin 40
Imidacloprid + Moxidectin 38
Cefpodoxime Proxetil 37
Gabapentin 35
Frunevetmab 29
Moxidectin 28
Cyclosporine A 27

Nationwide reactions with similar profiles

Two openFDA-derived peer sets for Pyoderma, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).

Similar death-coded share

Nearest other reactions by death-coded share (6.3% here), distinct from the volume row.

What to do with this reaction

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Pyoderma (#307 of 2,481 by report volume); death-coded 6.3%. PlainBreed reaction plate · report volume stamp 1,368 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →